M

Maat Pharma SA
PAR:MAAT

Watchlist Manager
Maat Pharma SA
PAR:MAAT
Watchlist
Price: 3.96 EUR -3.41% Market Closed
Market Cap: 63.9m EUR

Net Margin
Maat Pharma SA

-898.8%
Current
-913%
Average
-6.9%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-898.8%
=
Net Income
-28.9m
/
Revenue
3.2m

Net Margin Across Competitors

Maat Pharma SA
Glance View

Market Cap
63.9m EUR
Industry
Biotechnology

Maat Pharma SA operates as a clinical-stage microbiome therapeutics company. The company is headquartered in Lyon, Auvergne-Rhone-Alpes and currently employs 43 full-time employees. The company went IPO on 2021-11-08. The firm specializes in the microbiome therapy that is aimed to treatment of Gut Microbiota alteration (Dysbiosis) using patient-specific biotherapeutics in patients with serious medical conditions. Its MaaT Microbiome Restoration Therapy (MMRB) discovery and analysis platform supports the evaluation of drug candidates, the determination of new disease targets and the identification of biomarkers for microbiome-related conditions.

MAAT Intrinsic Value
HIDDEN
Show
What is Intrinsic Value?

See Also

Summary
MAAT intrinsic value, competitors valuation, and company profile.
DCF Valuation
MAAT stock valuation using Discount Cash Flow valuation method.
Relative Valuation
MAAT stock valuation using valuation multiples.
Wall Street Estimates
MAAT price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
MAAT stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-898.8%
=
Net Income
-28.9m
/
Revenue
3.2m
What is the Net Margin of Maat Pharma SA?

Based on Maat Pharma SA's most recent financial statements, the company has Net Margin of -898.8%.

Back to Top
ALPHA SPREAD
Follow us
Join more than 283,400+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.